PXD033530 is an
original dataset announced via ProteomeXchange.
Dataset Summary
Title | PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib |
Description | The synthetic lethal association between BRCA deficiency and poly (ADP-ribose) polymerase (PARP) inhibition supports PARP inhibitor (PARPi) clinical efficacy in BRCA-mutated tumors. PARPis also demonstrate activity in non-BRCA mutated tumors presumably through induction of PARP1-DNA trapping. Despite pronounced clinical response, therapeutic resistance to PARPis inevitably develops. An abundance of knowledge has been built around resistance mechanisms in BRCA-mutated tumors, however, parallel understanding in non-BRCA mutated settings remains insufficient. In this study, we find a strong correlation between the epithelial-mesenchymal transition (EMT) signature and resistance to a clinical PARPi, Talazoparib, in non-BRCA mutated tumor cells. Genetic profiling demonstrates that SNAI2, a master EMT transcription factor, is transcriptionally induced by Talazoparib treatment or PARP1 depletion and this induction is partially responsible for the emerging resistance. Mechanistically, we find that the PARP1 protein directly binds to SNAI2 gene promoter and suppresses its transcription. Talazoparib treatment or PARP1 depletion lifts PARP1-mediated suppression and increases chromatin accessibility around SNAI2 promoters, thus driving SNAI2 transcription and drug resistance. We also find that depletion of the chromatin remodeler CHD1L suppresses SNAI2 expression and reverts acquired resistance to Talazoparib. The PARP1/CHD1L/SNAI2 transcription axis might be therapeutically targeted to re-sensitize Talazoparib in non-BRCA mutated tumors. |
HostingRepository | PRIDE |
AnnounceDate | 2022-07-08 |
AnnouncementXML | Submission_2022-07-08_01:54:53.615.xml |
DigitalObjectIdentifier | https://dx.doi.org/10.6019/PXD033530 |
ReviewLevel | Peer-reviewed dataset |
DatasetOrigin | Original dataset |
RepositorySupport | Supported dataset by repository |
PrimarySubmitter | Xia Ding |
SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: 9606; |
ModificationList | No PTMs are included in the dataset |
Instrument | Orbitrap Fusion Lumos |
Dataset History
Revision | Datetime | Status | ChangeLog Entry |
0 | 2022-04-28 01:38:01 | ID requested | |
⏵ 1 | 2022-07-08 01:54:54 | announced | |
Publication List
Dataset with its publication pending |
Keyword List
submitter keyword: PARP1, Talazoparib, drug resistance |
Contact List
Todd VanArsdale |
contact affiliation | Tumor biology, Oncology Research Unit, Pfizer |
contact email | todd.vanarsdale@pfizer.com |
lab head | |
Xia Ding |
contact affiliation | Pfizer, Inc. |
contact email | xia.ding2@pfizer.com |
dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2022/07/PXD033530 |
PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD033530
- Label: PRIDE project
- Name: PARP1-SNAI2 Transcription Axis Drives Resistance to PARP Inhibitor, Talazoparib